Abstract
BackgroundAnti-tumour necrosis factor (anti-TNF) therapy has been widely used for refractory rheumatoid arthritis (RA) and psoriatic arthritis (PsA) over the past 10 years. Safety data from randomised controlled trials (RCTs)...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have